CD163 has been used as both a tumor-associated and M2 macrophage marker, CD169 has been used as a marker of subsets of macrophages in lymph nodes, lung, and GI tract independent of the M1/M2 classification system, and CD206 has been used as a general M2 marker [4, 37, 45, 46]. Here, SIGLEC1 is linked to neoplasm.